To start this activity, click Begin at the bottom of this pageThe Evaluation and Treatment of Resistant Hypertension

Release Date: October 2012

Expiration Date: October 2013

Estimated time to complete the educational activity: 1 hour

Continue Reading

This activity is jointly sponsored by Medical Education Resources and Haymarket Medical Education and is supported by an educational grant from Savient Pharmaceuticals.

Statement of Need: Primary care clinicians and nephrologists who care for patients with resistant hypertension must be able to identify truly resistant hypertension, as distinguished from pseudo resistance. Clinicians also need the tools to manage patients whose blood -pressure stubbornly resists control with traditional agents.

Target Audience: This activity has been designed to meet the educational needs of nephrologists and allied healthcare clinicians involved in the treatment of patients with resistant hypertension.

Educational Objectives: After completing the activity, the participant should be better able to:

  • Review the clinical predictors of resistant hypertension.
  • Distinguish resistant hypertension from pseudo resistance.
  • Evaluate current treatment modalities, and discuss experimental techniques to reduce blood pressure in patients with resistant hypertension.

Accreditation Statement:This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Haymarket Medical Education. MER is accredited by the ACCME to provide -continuing medical education for physicians.

Credit Designation:Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest: Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

Name of Faculty Reported Financial Relationship
Raymond V. Oliva, MD No financial relationships to disclose
George L. Bakris, MD Grants/Research Support: Takeda; Forest
Consultant: Takeda; Abbott; Eli Lilly; Medtronic, Relapsya
Speakers’ Bureau: Takeda

The content managers, Jody A. Charnow and Marina Galanakis, of Haymarket Medical Education, and Victoria C. Smith, MD, of Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest.

Method of Participation: There are no fees for participating in and receiving CME credit for this activity. During the period October 2012 through October 2013, participants must: 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest and submit it online. Physicians may register at, and 4) complete the evaluation form online.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.